A blog that publishes updates and open access scientific papers about allergy, asthma and immunology.
Editor: Juan Carlos Ivancevich, MD. Specialist in Allergy & Immunology
Antibiotic and oral corticosteroid prescribing rate in patients suffering from acute exacerbations of chronic obstructive pulmonary disease (COPD) or asthma in general practice are only sparsely described. Our aim was to identify predictors for such prescribing when results from CRP testing, spirometry, and pulse oximetry are available.
Many of the articles published in the ICC COLUMN have emphasized the plight that respiratory patients around the world have in obtaining satisfactory access to appropriate medications and health care. Two main problems have been identified. The first involves the high costs that prevent many patients from obtaining care (1). The second involves the difficulty to determine whether or not new medications, diagnostic procedures, and treatments actually do benefit patient outcomes. This paper provides an editor’s perspective on how the marketing activities of proprietary organizations make it difficult to assess published clinical research that is intended to determine the value of treatments.
Department of Paediatrics, Broomfield Hospital, Chelmsford, UK
Abstract
Upper airway obstruction (UAO) in infants and children has a broad spectrum of presentations including benign self-resolving conditions, from mild croup, to critical life-threatening conditions which, though uncommon now, require prompt recognition and effective multidisciplinary collaborative management to achieve a good outcome. The aim of this article is to highlight the diagnostic and management difficulties in acute UAO in paediatric patients and encourage a problem-solving approach.
The 300IR (index of reactivity) 5-grass pollen tablet has favorable short-term and sustained clinical efficacy in patients with grass pollen-induced allergic rhinoconjunctivitis (ARC). Here, we report maintenance of efficacy and safety over 2 years following treatment discontinuation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
State of the Art Reviews on Mechanisms of Allergic Disease
Authors
DOI: 10.1111/cea.12554View/save citation Summary Allergen immunotherapy (AIT) has been practised since 1911 and remains the only therapy proven to modify the natural history of allergic diseases. Although efficacious in carefully selected individuals, the currently licensed whole allergen extracts retain the risk of IgE-mediated adverse events, including anaphylaxis and occasionally death. This together with the need for prolonged treatment regimens results in poor patient adherence.
Please reference this document as follows: From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2015. Available from: http://www.ginasthma.org/.
For information about purchasing paper copies of GINA documents, or about using, adapting, or reproducing GINA materials, please contact us.
Low dose reactive cow's milk (CM) allergic children are at high risk of persistent CM allergy and a positive oral food challenge (OFC). The present study aimed to evaluate if the results of a very low dose (VL) OFC with these children contributes to better management of CM allergy.